Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Pay attention to the details!

There are multiple news releases now that have given us hints of very important upcoming events!

We will likely here about the following:

#1: Study protocol, timeline for study, for both the Korean study, and the Australian study (two separate studies!) Our portfolio is diversifying by the moment. Algernon thinks the drug will be in the sick patients ASAP.

March 20, 2020 14:22 ET | Source: Algernon Pharmaceuticals

VANCOUVER, British Columbia, March 20, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce today that it has chosen to appoint award winning Novotech as the contract research organization (“CRO”) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea. Novotech is an internationally recognized full service CRO known for its experience across Australia, New Zealand, Asia and South Africa, representing emerging markets with a population base of over 3 billion people.

Novotech will be working to assist the investigators of the planned and SPONSORED study, including supporting all aspects of the clinical trial. After the trial is approved, the Company will provide full details on the study protocol and timelines.

The Company also wishes to advise that it has retained Novotech to conduct a feasibility study in Australia for a phase 2 sponsor initiated Ifenprodil COVID-19 trial. Novotech has already identified 3 physicians who have indicated their interest to participate. The Company will update the market shortly.

“Novotech was a natural CRO choice for us to help to support this important investigator-led clinical trial,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Since Ifenprodil is an already approved drug with a known safety history, we look forward to expedited steps that will make it available to patients as soon as possible under the study guidelines.”

#2: Gates...! Funding !

Algernon Pharmaceuticals: Algernon Contacts Gates Foundation Regarding Funding for New Coronavirus Treatments

#3: Pre-IND with the FDA... ! Trump has specifically said that repurposed drugs will be the target and we have a US Department of Energy publication which revealed the SUMMIT super computer picked up Ifenprodil as potentially decreasing the infectivity of coronavirus (in addition to our animal studies which show 40% mortality reduction! Two separate mechanisms! Double bang for our buck and maybe twice as effective, or maybe even SYNERGY (more than twice!)

Algernon Pharmaceuticals
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

Worlds fastest supercomputer identifies Ifenprodil as drug target for decreasing infectivity of coronavirus

#3: THE DRUG...! Scale up production! !

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).

The decision was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. This compelling data, generated via a genome wide RNAi interference approach, that lead the investigators to the identification of Ifenprodil, an NMDA receptor antagonist, has been a major contributing factor in the Company’s decision.

The Company is in negotiations with a number of manufacturers and will be announcing more details on its decision shortly.

“The Company believes strongly in the potential of Ifenprodil to treat patients who have a severe acute lung injury, including people who have various forms of respiratory infections including COVID-19 (coronavirus) and influenza,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon has filed new intellectual property rights for NP-120 (Ifenprodil) for the treatment of respiratory diseases.

Which manufacturer will they choose?!?